摘要
目的检测慢性心力衰竭（CHF）患者血浆硫化氢水平变化情况，并探讨其相关临床意义。方法选择118例CHF患者，按照NYHA心功能分级标准分级：II级34例、Ⅲ级54例、Ⅳ级30例，按随机数字表法分为常规治疗组和硝普钠治疗组，每组59例。另选择30例健康体检者作为对照组。治疗前后采用去蛋白法测定血浆硫化氢水平。结果CHF患者血浆硫化氢水平为（32．45±3．86）μmol／L，低于健康体检者的（54．26±5．63）μmol／L，差异有统计学意义（P〈0．05）。心功能Ⅱ、Ⅲ、Ⅳ级CHF患者血浆硫化氢水平分别为（43．26±4．73）、（31．87±4．12）、（23．66±3．54）μmol／L，各分级间比较差异有统计学意义（P〈0．05）。常规治疗组和硝普钠治疗组治疗前血浆硫化氢水平分别为（31．66±3．75）、（33．04±4．02）μmol／L，两组比较差异无统计学意义（P〉0．05）；常规治疗组和硝普钠治疗组治疗后血浆硫化氢水平分别为（36．83±4．32）、（44．54±4．68）μmol／L，两组比较差异有统计学意义（P〈0．05）；两组治疗后血浆硫化氢水平均较本组治疗前显著升高，差异有统计学意义（P〈0．05）。常规治疗组显效11例，有效14例，总有效率为42．4％（25，59）；硝普钠治疗组显效22例，有效18例，总有效率为67．8％（40／59），两组总有效率比较差异有统计学意义（P〈0．05）。结论血浆硫化氢水平的异常可能参与了CHF的发生、发展过程，并与CHF病情的严重程度密切相关，升高血浆硫化氢水平可以显著改善CHF患者的临床预后。
Objective To detect the change of the plasma hydrogen sulfide in patients with chronic heart failure （CHF） and explore its clinical significance. Methods A total of 118 patients with CHF was enrolled in this study. According to the NYHA standard, they were classified into grade I1 （34 cases）, grade III （54 cases）,grade IV （30 cases）. The patients were divided into normal treatment group and sodium nitroprusside treatment group with 59 cases each. Another 30 healthy person were selected as control group. The plasma hydrogen sulfide level was detected by spectrophotometer. Results The plasma hydrogen sulfide level in CHF patients and healthy person was （32.45 ± 3.86）, （54.26 ± 5.63） μmol/L, and there was significant difference （P〈 0.05）. The plasma hydrogen sulfide level in CHF patients of grade Ⅱ , Ⅲ, Ⅳ was （43.26 ± 4.73）, （31.87 ± 4.12）, （23.66 ± 3.54） μmol/L,and there was significant difference （P 〈 0.05）. The plasma hydrogen sulfide level before treatment in normal treatment group and sodium nitroprusside treatment group was （31.66 ± 3.75 ）, （33.04 ±4.02 ） μmol/L, and there was no significant difference between two groups （P 〉 0.05）. The plasma hydrogen sulfide level after treatment in normal treatment group and sodium nitroprusside treatment group was （36.83 ± 4.32）, （44.54± 4.68 ） μmol/L, and there was significant difference （P 〈0.05）. The plasma hydrogen sulfide level after treatment in two groups was increased compared with that before treatment, and there was significant difference （P 〈 0.05）. The total effective rate in normal treatment group and sodium nitroprusside treatment group was 42.4%（25/59） and 67.8%（40/59）, and there was significant difference between two groups （P 〈 0.05）. Conclusions The abnormal plasma hydrogen sulfide level may be involved in the occurrence and development process of CHF, which could be used as a factor to monitor the disease. The upregulation of plasma hydrogen sulfide level can significantly improve the prognosis of CHF patients.
出处
《中国医师进修杂志》
2013年第7期4-6,共3页
Chinese Journal of Postgraduates of Medicine
关键词
心力衰竭
硫化氢
硝普钠
Heart failure
Hydrogen sulfide
Sodium nitroprusside
